Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment

Journal of Controlled Release

Volumn 101, Issue 1-3 SPEC. ISS., 2005, Pages 273-285

  Janát Amsbury, Margit Maria ^a   Yockman, James W ^a   Lee, Minhyung ^a,b   Kern, Steven ^a   Furgeson, Darin Y ^a   Bikram, Malavosklish ^a   Kim, Sung Wan ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Inha University School of Medicine   (South Korea)

Author keywords

Breast cancer; Interleukin 12; Lipopolymer; Non viral gene delivery; Paclitaxel; Water soluble

Indexed keywords

BIOCOMPATIBILITY; CHEMOTHERAPY; IMMUNOLOGY; POLYMERS; PROBLEM SOLVING; TUMORS;

GENE DELIVERY; GENE TRANSFER METHODS; LIPOPOLYMERS; TUMOR VOLUME;

GENES;

ANTINEOPLASTIC AGENT; COPOLYMER; CREMOPHOR; HYSOLV; LIPOPOLYMER; PACLITAXEL; POLY(LACTIDE CO GLYCOLIDE)POLYETHYLENE GLYCOL POLY(LACTIDE CO GLYCOLIDE); POLYMER; RECOMBINANT INTERLEUKIN 12; SOLUBILIZER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIODEGRADABILITY; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COMPLEX FORMATION; CONFERENCE PAPER; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RESPONSE; FEMALE; LUNG METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 10044281803     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.08.015     Document Type: Conference Paper

References (47)

1. S. Han, R.I. Mahato, Y.K. Sung, and S.W. Kim Development of biomaterials for gene therapy Molec. Ther. 2 2000 302 317
2. S. Han, R.I. Mahato, and S.W. Kim Water-soluble lipopolymer for gene delivery Bioconjug. Chem. 12 2001 337 345
3. M. Whitmore, S. Li, and L. Huang LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth Gene Ther. 6 1999 1867 1875
4. M.M. Whitmore, S. Li, L. Falo Jr., and L. Huang Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses Cancer Immunol. Immunother. 50 2001 503 514
5. J.W. Yockman, A. Maheshwari, S. Han, and S.W. Kim Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes J. Control. Release 87 2003 177 186
6. H. Gahery-Segard, F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J.G. Guillet Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity J. Virol. 72 1998 2388 2397
7. V. Molinier-Frenkel, H. Gahery-Segard, M. Mehtali, C. Le Boulaire, S. Ribault, P. Boulanger, T. Tursz, J.G. Guillet, and F. Farace Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes J. Virol. 74 2000 7678 7682
8. M.J. Brunda, L. Luistro, R.R. Warrier, R.B. Wright, B.R. Hubbard, M. Murphy, S.F. Wolf, and M.K. Gately Antitumor and antimetastatic activity of interleukin 12 against murine tumors J. Exp. Med. 178 1993 1223 1230
9. M.J. Brunda, and M.K. Gately Interleukin-12: potential role in cancer therapy Important Adv. Oncol. 1995 3 18
10. D.W. Mullins, M.D. Koci, C.J. Burger, and K.D. Elgert Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation Immunopharmacol. Immunotoxicol. 20 1998 473 492
11. A.L. Rakhmilevich, K. Janssen, Z. Hao, P.M. Sondel, and N.S. Yang Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism Cancer Gene Ther. 7 2000 826 838
12. J. Cohen IL-12 deaths: explanation and a puzzle Science 270 1995 908
13. D. Radice, and A. Redaelli Breast cancer management: quality-of-life and cost considerations PharmacoEconomics 21 2003 383 396
14. C. Farquhar, R. Basser, S. Hetrick, A. Lethaby, and J. Marjoribanks High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer Cochrane Database Syst. Rev. 2003 CD003142
15. D.W. Mullins, C.J. Burger, and K.D. Elgert Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide J. Immunol. 162 1999 6811 6818
16. S.G. Arbuck, A. Dorr, and M.A. Friedman Paclitaxel (Taxol) in breast cancer Hematol./Oncol. Clin. North Am. 8 1994 121 140
17. W.J. Loos, J. Szebeni, A.J. ten Tije, J. Verweij, D.M. van Zomeren, K.N. Chung, K. Nooter, G. Stoter, and A. Sparreboom Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel Anticancer Drugs 13 2002 767 775
18. R.T. Dorr Pharmacology and toxicology of Cremophor EL diluent Ann. Pharmacother. 28 1994 S11 S14
19. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. Baker Jr., D.A. Van Echo, D.D. Von Hoff, and B. Leyland-Jones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1990 1263 1268
20. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
21. R.I. Mahato, M. Lee, S. Han, A. Maheshwari, and S.W. Kim Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers Molec. Ther. 4 2001 130 138
22. C.J. Aslakson, and F.R. Miller Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res. 52 1992 1399 1405
23. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S. Cowan, and M.J. Egorin Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8 2002 878 884
24. G.M. Zentner, R. Rathi, C. Shih, J.C. McRea, M.H. Seo, H. Oh, B.G. Rhee, J. Mestecky, Z. Moldoveanu, M. Morgan, and S. Weitman Biodegradable block copolymers for delivery of proteins and water-insoluble drugs J. Control. Release 72 2001 203 215
25. P. Sampath, E. Amundson, M.E. Wall, B.M. Tyler, M.C. Wani, L.M. Alderson, M. Colvin, H. Brem, and J.D. Weingart Camptothecin analogs in malignant gliomas: comparative analysis and characterization J. Neurosurg. 98 2003 570 577
26. J.L. Fox Gene therapy safety issues come to fore Nat. Biotechnol. 17 1999 1153
27. F. Cavallo, E. Di Carlo, M. Butera, R. Verrua, M.P. Colombo, P. Musiani, and G. Forni Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12 Cancer Res. 59 1999 414 421
28. R.A. Seder, R. Gazzinelli, A. Sher, and W.E. Paul Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming Proc. Natl. Acad. Sci. U. S. A. 90 1993 10188 10192
29. S.H. Chan, B. Perussia, J.W. Gupta, M. Kobayashi, M. Pospisil, H.A. Young, S.F. Wolf, D. Young, S.C. Clark, and G. Trinchieri Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers J. Exp. Med. 173 1991 869 879
30. S.F. Wolf, D. Sieburth, and J. Sypek Interleukin 12: a key modulator of immune function Stem Cells 12 1994 154 168
31. M. Strasly, F. Cavallo, M. Geuna, S. Mitola, M.P. Colombo, G. Forni, and F. Bussolino IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk J. Immunol. 166 2001 3890 3899
32. B.A. Pulaski, M.J. Smyth, and S. Ostrand-Rosenberg Interferon-gamma- dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma Cancer Res. 62 2002 4406 4412
33. M.J. Smyth, K.Y. Thia, S.E. Street, E. Cretney, J.A. Trapani, M. Taniguchi, T. Kawano, S.B. Pelikan, N.Y. Crowe, and D.I. Godfrey Differential tumor surveillance by natural killer (NK) and NKT cells J. Exp. Med. 191 2000 661 668
34. L.R. Wiseman, and C.M. Spencer Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers Drugs Aging 12 1998 305 334
35. P.Y. Perera, T.N. Mayadas, O. Takeuchi, S. Akira, M. Zaks-Zilberman, S.M. Goyert, and S.N. Vogel CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression J. Immunol. 166 2001 574 581
36. R.R. Nair, J.R. Rodgers, and L.A. Schwarz Enhancement of transgene expression by combining glucocorticoids and anti-mitotic agents during transient transfection using DNA-cationic liposomes Molec. Ther. 5 2002 455 462
37. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 1999 1454 1457
38. J. Szebeni, F.M. Muggia, and C.R. Alving Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study J. Natl. Cancer Inst. 90 1998 300 306
39. H. Maeda, and Y. Matsumura Tumoritropic and lymphotropic principles of macromolecular drugs Crit. Rev. Ther. Drug Carr. Syst. 6 1989 193 210
40. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
41. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Jpn. J. Cancer Res. 89 1998 307 314
42. G. Bonadonna, P. Valagussa, C. Brambilla, L. Ferrari, A. Moliterni, M. Terenziani, and M. Zambetti Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J. Clin. Oncol. 16 1998 93 100
43. H. Seidman, S.K. Gelb, E. Silverberg, N. LaVerda, and J.A. Lubera Survival experience in the Breast Cancer Detection Demonstration Project CA Cancer J. Clin. 37 1987 258 290
44. M. Kaufmann, and F. Kubli Current state of chemosensitivity testing of tumors Dtsch. Med. Wochenschr. 108 1983 150 154
45. G. von Minckwitz, S.D. Costa, W. Eiermann, J.U. Blohmer, A.H. Tulusan, C. Jackisch, and M. Kaufmann Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel J. Clin. Oncol. 17 1999 1999 2005
46. W.K. Kang, C. Park, H.L. Yoon, W.S. Kim, S.S. Yoon, M.H. Lee, K. Park, K. Kim, H.S. Jeong, J.A. Kim, S.J. Nam, J.H. Yang, Y.I. Son, C.H. Baek, J. Han, H.J. Ree, E.S. Lee, S.H. Kim, D.W. Kim, Y.C. Ahn, S.J. Huh, Y.H. Choe, J.H. Lee, M.H. Park, G.S. Kong, E.Y. Park, Y.K. Kang, Y.J. Bang, N.S. Paik, S.N. Lee, S. Kim, P.D. Robbins, H. Tahara, M.T. Lotze, and C.H. Park Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study Hum. Gene Ther. 12 2001 671 684
47. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 2003 319 328